Bonus BioGroup Ltd. (BBIXF)
USD 0.02
(0.0%)
USD 0.02
(0.0%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 11.15 Million ILS | -6.64% |
| 2022 | 11.95 Million ILS | -3.22% |
| 2021 | 12.35 Million ILS | 139.62% |
| 2020 | 5.15 Million ILS | -12.29% |
| 2019 | 5.87 Million ILS | 0.0% |
| 2018 | - ILS | 0.0% |
| 2017 | - ILS | 0.0% |
| 2016 | - ILS | 0.0% |
| 2015 | - ILS | -100.0% |
| 2014 | 671 Thousand ILS | 0.0% |
| 2013 | - ILS | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q2 | 10.72 Million ILS | -1.4% |
| 2024 Q1 | 10.87 Million ILS | -2.54% |
| 2023 Q4 | 11.15 Million ILS | -2.58% |
| 2023 Q2 | 11.66 Million ILS | -1.13% |
| 2023 Q3 | 11.45 Million ILS | -1.8% |
| 2023 FY | 11.15 Million ILS | -6.64% |
| 2023 Q1 | 11.79 Million ILS | -1.31% |
| 2022 Q1 | 12.12 Million ILS | -1.81% |
| 2022 FY | 11.95 Million ILS | -3.22% |
| 2022 Q4 | 11.95 Million ILS | -0.23% |
| 2022 Q3 | 11.97 Million ILS | -0.28% |
| 2022 Q2 | 12.01 Million ILS | -0.93% |
| 2021 Q3 | 12.76 Million ILS | 4018.71% |
| 2021 FY | 12.35 Million ILS | 139.62% |
| 2021 Q2 | 310 Thousand ILS | -93.75% |
| 2021 Q1 | 4.95 Million ILS | -3.8% |
| 2021 Q4 | 12.35 Million ILS | -3.27% |
| 2020 Q4 | 5.15 Million ILS | -3.07% |
| 2020 FY | 5.15 Million ILS | -12.29% |
| 2020 Q3 | 5.31 Million ILS | -3.29% |
| 2020 Q2 | 5.49 Million ILS | -2.95% |
| 2020 Q1 | 5.66 Million ILS | -3.59% |
| 2019 Q4 | 5.87 Million ILS | -2.28% |
| 2019 Q2 | 6.18 Million ILS | -1.56% |
| 2019 Q1 | 6.28 Million ILS | 0.0% |
| 2019 FY | 5.87 Million ILS | 0.0% |
| 2019 Q3 | 6.01 Million ILS | -2.78% |
| 2018 Q2 | - ILS | 0.0% |
| 2018 FY | - ILS | 0.0% |
| 2018 Q4 | - ILS | 0.0% |
| 2018 Q1 | - ILS | 0.0% |
| 2018 Q3 | - ILS | 0.0% |
| 2017 Q1 | - ILS | 0.0% |
| 2017 Q3 | - ILS | 0.0% |
| 2017 Q4 | - ILS | 0.0% |
| 2017 FY | - ILS | 0.0% |
| 2017 Q2 | - ILS | 0.0% |
| 2016 Q2 | - ILS | 0.0% |
| 2016 Q1 | - ILS | 0.0% |
| 2016 FY | - ILS | 0.0% |
| 2016 Q4 | - ILS | 0.0% |
| 2016 Q3 | - ILS | 0.0% |
| 2015 Q2 | - ILS | 0.0% |
| 2015 Q1 | - ILS | -100.0% |
| 2015 FY | - ILS | -100.0% |
| 2015 Q4 | - ILS | 0.0% |
| 2015 Q3 | - ILS | 0.0% |
| 2014 Q4 | 671 Thousand ILS | 0.0% |
| 2014 Q2 | - ILS | 0.0% |
| 2014 Q1 | - ILS | 0.0% |
| 2014 FY | 671 Thousand ILS | 0.0% |
| 2014 Q3 | - ILS | 0.0% |
| 2013 Q3 | - ILS | 0.0% |
| 2013 FY | - ILS | 0.0% |
| 2013 Q2 | - ILS | 0.0% |
| 2013 Q4 | - ILS | 0.0% |
| 2013 Q1 | - ILS | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| Eiger BioPharmaceuticals, Inc. | 41.2 Million USD | 72.919% |
| Nanobac Pharmaceuticals, Incorporated | 4.12 Million USD | -170.697% |
| SQZ Biotechnologies Company | 27.47 Million USD | 59.383% |
| Evofem Biosciences, Inc. | 43.37 Million USD | 74.274% |
| Santhera Pharmaceuticals Holding AG | 29.76 Million USD | 62.516% |
| Mesoblast Limited | 118.7 Million USD | 90.6% |
| Propanc Biopharma, Inc. | 948.27 Thousand USD | -1076.668% |
| Genus plc | 233.1 Million USD | 95.213% |
| VioQuest Pharmaceuticals, Inc. | 2.93 Million USD | -280.769% |
| CNBX Pharmaceuticals Inc. | 1.34 Million USD | -730.465% |
| Marizyme, Inc. | 18.71 Million USD | 40.387% |
| ContraFect Corporation | 2.88 Million USD | -287.296% |
| Nymox Pharmaceutical Corporation | 750 Thousand USD | -1387.733% |
| PsyBio Therapeutics Corp. | 135.48 Thousand USD | -8135.476% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 1.44 Million USD | -671.476% |
| Intellipharmaceutics International Inc. | 2.32 Million USD | -379.717% |
| AXIM Biotechnologies, Inc. | 5.65 Million USD | -97.195% |
| MultiCell Technologies, Inc. | 202.58 USD | -5507847.478% |
| Accustem Sciences Inc. | - USD | -Infinity% |
| RVL Pharmaceuticals plc | 57.48 Million USD | 80.591% |
| EV Biologics, Inc. | 1.49 Million USD | -646.479% |
| Q BioMed Inc. | 4.1 Million USD | -171.485% |
| Emmaus Life Sciences, Inc. | 33.1 Million USD | 66.291% |
| Neon Bloom, Inc. | 630.07 Thousand USD | -1670.895% |
| Mosaic ImmunoEngineering Inc. | 1.22 Million USD | -808.365% |
| Biomind Labs Inc. | 735.54 Thousand USD | -1416.977% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Pharming Group N.V. | 171.54 Million USD | 93.496% |
| Oncotelic Therapeutics, Inc. | 12.99 Million USD | 14.149% |
| Skye Bioscience, Inc. | 4.61 Million USD | -141.763% |
| Therapeutic Solutions International, Inc. | 888.06 Thousand USD | -1156.441% |
| THC Farmaceuticals, Inc. | 141.51 Thousand USD | -7784.509% |
| Arch Therapeutics, Inc. | 5.87 Million USD | -90.05% |
| IMV Inc. | 28.88 Million USD | 61.369% |
| Acro Biomedical Co., Ltd. | 25.71 Thousand USD | -43284.268% |
| Curative Biotechnology, Inc. | 2.25 Million USD | -394.071% |
| GB Sciences, Inc. | 1.75 Million USD | -534.227% |
| Alpha Cognition Inc. | 1.22 Million USD | -814.311% |
| HST Global, Inc. | 98.31 Thousand USD | -11248.773% |
| CSL Limited | 12.18 Billion USD | 99.908% |
| Halberd Corporation | 150 Thousand USD | -7338.667% |
| Enzolytics Inc. | 996.33 Thousand USD | -1019.901% |
| Resverlogix Corp. | 6.49 Million USD | -71.9% |
| Affymax, Inc. | - USD | -Infinity% |
| SYBLEU INC | 477.5 Thousand USD | -2236.754% |
| Nuo Therapeutics, Inc. | 255.59 Thousand USD | -4265.551% |
| argenx SE | 20 Million USD | 44.21% |
| MetaStat, Inc. | - USD | -Infinity% |
| Northwest Biotherapeutics, Inc. | 45.56 Million USD | 75.509% |
| Enzon Pharmaceuticals, Inc. | - USD | -Infinity% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| RespireRx Pharmaceuticals Inc. | 2.7 Million USD | -311.931% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | - USD | -Infinity% |
| AVAX Technologies, Inc. | - USD | -Infinity% |
| Zenith Capital Corp. | 10.22 Thousand USD | -109024.694% |
| Genscript Biotech Corporation | 417.73 Million USD | 97.329% |
| Ember Therapeutics, Inc. | 200.61 Thousand USD | -5461.869% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 2.39 Million USD | -365.358% |
| WPD Pharmaceuticals Inc. | 229.29 Thousand USD | -4766.305% |
| American Oriental Bioengineering, Inc. | 67.64 Million USD | 83.505% |
| Provectus Biopharmaceuticals, Inc. | 3.02 Million USD | -268.714% |
| Adynxx, Inc. | - USD | -Infinity% |
| Helix BioMedix, Inc. | - USD | -Infinity% |
| GlobeStar Therapeutics Corporation | 359.71 Thousand USD | -3001.943% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 20.32 Million USD | 45.11% |
| Cotinga Pharmaceuticals Inc. | 148.65 Thousand USD | -7406.021% |
| BioStem Technologies, Inc. | 4.71 Million USD | -136.829% |
| ONE Bio Corp. | 19.71 Million USD | 43.404% |
| Reve Technologies, Inc. | 250.18 Thousand USD | -4359.953% |
| Burzynski Research Institute, Inc. | - USD | -Infinity% |
| Wesana Health Holdings Inc. | 248.72 Thousand USD | -4386.169% |
| Agentix Corp. | 50 Thousand USD | -22216.0% |
| LadRx Corporation | 33.6 Thousand USD | -33102.404% |
| Cell Source, Inc. | 9.25 Million USD | -20.573% |
| ProtoKinetix, Incorporated | - USD | -Infinity% |
| Regen BioPharma, Inc. | 756.2 Thousand USD | -1375.528% |
| Regen BioPharma, Inc. | 756.2 Thousand USD | -1375.528% |
| NovAccess Global Inc. | 2.19 Million USD | -407.209% |
| Endonovo Therapeutics, Inc. | 7.07 Million USD | -57.759% |
| Itoco Inc. | 228.37 Thousand USD | -4785.781% |
| Rasna Therapeutics, Inc. | 210.97 Thousand USD | -5188.778% |
| Pathfinder Cell Therapy, Inc. | 4.98 Million USD | -123.921% |
| Kadimastem Ltd | 891.22 Thousand USD | -1151.983% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Institute of Biomedical Research Corp. | 401.84 Thousand USD | -2676.665% |
| CytoDyn Inc. | 30.07 Million USD | 62.901% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | - USD | -Infinity% |
| Mobile Lads Corp. | 484.28 Thousand USD | -2204.02% |
| NanoSphere Health Sciences Inc. | - USD | -Infinity% |
| Qrons Inc. | 351.84 Thousand USD | -3071.265% |
| Alseres Pharmaceuticals, Inc. | 7.81 Million USD | -42.686% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| Nascent Biotech, Inc. | 122.5 Thousand USD | -9008.571% |
| Rebus Holdings, Inc. | 310 Thousand USD | -3499.355% |
| ImmunoCellular Therapeutics, Ltd. | 4.73 Million USD | -135.635% |
| International Stem Cell Corporation | 4.17 Million USD | -167.066% |
| Bioxytran, Inc. | 1.92 Million USD | -479.636% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 62.41 Thousand USD | -17777.686% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 2.18 Million USD | -411.624% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 8.31 Million USD | -34.175% |
| Adhera Therapeutics, Inc. | 8.58 Million USD | -29.971% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 1.55 Million USD | -617.335% |
| Innovation Pharmaceuticals Inc. | 268 Thousand USD | -4063.433% |
| Neutra Corp. | 54.15 Thousand USD | -20503.442% |
| Windtree Therapeutics, Inc. | 1.83 Million USD | -509.727% |
| PureTech Health plc | 25.51 Million USD | 56.264% |
| Coeptis Therapeutics, Inc. | 1.22 Million USD | -811.433% |
| IXICO plc | 472.02 Thousand USD | -2263.868% |
| IntelGenx Technologies Corp. | 15.5 Million USD | 28.018% |
| Gelesis Holdings, Inc. | 62.26 Million USD | 82.079% |
| CSL Limited | 12.18 Billion USD | 99.908% |
| Cellectis S.A. | 92.77 Million USD | 87.973% |